Today: 5 April 2026
Subscribe
Browse Category

Stock Market 17 October 2025

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences shares rose to $123 on October 17, 2025, up nearly 40% from a year ago, lifting its market value to about $150 billion. The company settled U.S. patent litigation over HIV drug Biktarvy, blocking generics until 2036. Its new HIV prevention shot Yeztugo is seeing strong uptake, and Moody’s raised Gilead’s outlook to “Positive.” Gilead also announced a $1.5 billion cell therapy deal with Pregene.
17 October 2025
··
Rekor Systems (REKR) Stock Rockets 73% on AI-Powered Roadway Tech Breakthroughs

Rekor Systems (REKR) Stock Rockets 73% on AI-Powered Roadway Tech Breakthroughs

Rekor Systems shares surged about 20% to $3.17 on Oct. 17, extending a 73% rally over the past month after the company previewed record Q3 revenue and major new contracts. Rekor won a $50M+ Georgia DOT deal, deployments with Caltrans and TxDOT, and a $1M South Carolina order. The price-to-sales ratio now matches the industry median as investors anticipate 19% revenue growth next year.
17 October 2025
··
Liberty Energy’s Rollercoaster: LBRT Surges on Earnings Despite Oilfield Headwinds

Liberty Energy’s Rollercoaster: LBRT Surges on Earnings Despite Oilfield Headwinds

Liberty Energy shares jumped over 20% intraday on October 17 after reporting Q3 revenue of $947 million, down 17% year-over-year, and an adjusted net loss of $0.06 per share. Despite the rebound, LBRT remains about 40% lower year-to-date, closing at $11.94 on October 16. The company raised its quarterly dividend by 13% to $0.09 per share. Analyst price targets cluster around $13–$15 for the next year.
17 October 2025
····
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences said the FDA canceled a key meeting and imposed new trial demands for its lead drug zetomipzomib, delaying development by about two years. The company is now exploring a sale or merger and cutting costs. Shares jumped nearly 40% to $6 on Oct. 17. Kezar reported $90.2 million in cash as of Sept. 30 but faces higher expenses and extended a poison pill plan to 2026.
17 October 2025
··
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine shares jumped 25.5% to $93 on October 17, 2025, after the FDA granted a Commissioner’s National Priority Voucher for its lead drug, bitopertin. The company filed a New Drug Application for bitopertin in late September; with the voucher, an approval decision could come as soon as late December. Several analysts raised their price targets sharply following the FDA news.
17 October 2025
·
Nebius (NBIS) Stock Rockets on $17B Microsoft AI Deal – Explosive Growth & Outlook Revealed

Nebius Group (NBIS) Skyrockets 350% on AI Deal, Then Stumbles – What’s Next for This Cloud Newcomer?

Nebius Group (NASDAQ: NBIS) stock soared over 350% year-to-date, fueled by a $17.4 billion AI infrastructure deal with Microsoft in September that triggered a one-day 44% jump. Shares cooled to $114 on Oct. 17, down 7% amid heavy profit-taking. The company raised $1.3 billion recently to fund a $3 billion expansion of its AI cloud capacity. Q2 revenue surged 625% to $105.1 million, but Nebius remains unprofitable.
17 October 2025
···
Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Regions Financial Stock Surges on Strong Q3 Profit; Analysts Upbeat on Outlook

Regions Financial shares rose about 2% on Oct. 17 after posting Q3 profit of $548 million, up 23% from a year ago, and adjusted EPS of $0.63, beating forecasts. Revenue climbed 7% to $1.9 billion. The board raised the quarterly dividend 6% to $0.265 per share. Management trimmed full-year net interest income guidance but reported improved asset quality and steady deposit growth.
17 October 2025
··
VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

VirnetX Stock Soars 71% on Major Government Contract – What’s Next for VHC?

VirnetX Holding Corp’s stock surged as much as 71% on Oct. 17 after announcing a General Services Administration contract, reaching a 30-month high near $29 before settling in the low $20s by midday. The deal designates VirnetX as an approved technology provider for U.S. government agencies, expanding federal market access. Market cap rose to about $75 million. CEO Kendall Larsen called the contract a “major step forward.”
17 October 2025
··
Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Stock Surges on Bitcoin Treasury Strategy and Expansion Plans

Harrison Global Holdings shares rose about 12% to $0.22 on Oct. 17 after announcing a binding term sheet with White Lion Capital for a Bitcoin Purchase Agreement. Pre-market trading saw the stock spike to $0.23. The company also revealed plans for a ¥10 billion fund with European partners to promote Asian media content. No Wall Street analysts cover BLMZ; AI models project modest further gains.
17 October 2025
··
Newmont Stock Skyrockets as Gold Rally Hits Record Highs – Will the Boom Continue?

Newmont Stock Skyrockets on Gold Boom: Record Highs, $100 B Milestone & Bold Forecasts

Newmont Corporation shares surged nearly 15% this week, pushing its market value above $100 billion for the first time. The rally follows gold prices hitting record highs above $4,300 per ounce amid geopolitical tensions and Fed rate cut expectations. Major banks raised price targets, with Bank of America setting a $115 target on October 16. Newmont reports Q3 earnings October 23, with analysts forecasting a 58% profit jump.
17 October 2025
··
Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

Huntington Bancshares’ Profit Surge Defies Banking Jitters – HBAN Stock Eyes Rebound

Huntington Bancshares stock rose 2% to the mid-$15 range on Oct. 17, 2025, after Q3 net income jumped 22% to $629 million, beating estimates. Revenue reached $2.15 billion, with interest income up 11% and non-interest income up 20%. Average loans grew 9%, while net charge-offs stayed low at 0.22%. The bank is set to close its merger with Veritex Holdings on Oct. 20.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
Fifth Third’s Stock Jumps on Earnings Beat and Mega-Merger – Is FITB a Buy Now?

Fifth Third’s Stock Jumps on Earnings Beat and Mega-Merger – Is FITB a Buy Now?

Fifth Third Bancorp shares rose 2–3% to the low $40s on Oct. 17 after Q3 profit jumped 14% to $608 million, beating analyst estimates. The rebound followed a 4% drop the previous day amid regional bank credit fears. Net interest income climbed 7% to $1.53 billion, helped by easing deposit costs. Earlier this month, Fifth Third announced a $10.9 billion all-stock deal to acquire Comerica.
17 October 2025
····
SLB Stock Q3 Beat, $4B Buybacks & Oil Swoon: Will Schlumberger (SLB) Rebound?

SLB Stock Q3 Beat, $4B Buybacks & Oil Swoon: Will Schlumberger (SLB) Rebound?

SLB N.V. shares traded near $33 on Oct. 17, 2025, down over 20% from a year ago despite beating Q3 earnings estimates with $0.69 EPS and $8.93 billion revenue. The company closed a $7.7 billion merger with ChampionX in July, adding $595 million to Q3 revenue. Oil prices fell to $61 Brent, pressuring international revenue, which dropped 7% year-over-year. SLB plans at least $4 billion in shareholder payouts for 2025.
17 October 2025
···
American Express Raises Forecasts Amid Spending Boom – Is AXP Stock Poised to Soar?

American Express Raises Forecasts Amid Spending Boom – Is AXP Stock Poised to Soar?

American Express reported record third-quarter revenue of $18.4 billion, up 11% year-over-year, and raised its 2025 outlook after earnings beat estimates at $4.14 per share. Shares hit an all-time high of $349.19 before pulling back to around $330. Affluent cardholder spending rose 12% year-over-year, with no sign of slowdown. Analysts remain broadly positive, with most rating the stock a Buy.
17 October 2025
··
Shell’s $2 Billion Nigeria Gas Gamble Ignites LNG Boom Amid $8 B Investment Surge

Shell’s Bold $2 Billion Bet and Oil Price Twist: What’s Next for Shell Stock?

Shell plc shares closed at 2,672 pence in London on October 17, up 3.6% for the week after volatile trading. The company approved a $2 billion offshore gas project in Nigeria and raised its Q3 outlook, with analysts forecasting strong earnings on October 30. Brent crude hovered near $62 a barrel, pressuring valuations, but Shell continued buybacks. Twelve analysts rate the stock “Buy,” with a target near 3,100 GBp.
17 October 2025
··
Lloyds Share Price: Can the FTSE‑100 Bank’s Value Keep Surging or Is a Crash Coming?

Lloyds Stock Nears Decade High as Bank Shrugs Off £2bn Scandal Hit

Lloyds Banking Group shares rebounded from an early 3% drop to trade near 85 pence on Friday, close to a 10-year high. The bank added £800 million to provisions for a UK car loan mis-selling scandal, bringing total charges to £1.95 billion. Lloyds’ stock is up about 50% year-on-year, defying a broader bank selloff. First-half net interest income rose 5% to £6.7 billion.
17 October 2025
·
1 … 1,304 1,305 1,306 1,307 1,308 … 1,371

Stock Market Today

  • St. James's Place Investment Outlook Shifts With Analyst Target Adjustments
    April 5, 2026, 12:51 PM EDT. St. James's Place (LSE:STJ) faces a mixed outlook as analyst price targets diverge sharply. The fair value estimate edged down slightly to £16.62 per share, reflecting security in the long-term earnings but caution on execution and technological disruption. Citi and Deutsche Bank raised targets, signalling confidence if the company executes well. UBS and other firms see current valuations as pricing in many risks. Conversely, Barclays downgraded its target to £13, citing artificial intelligence as a threat to the advice-driven model and potential fee pressures. JPMorgan trimmed targets due to regulatory and execution concerns. Meanwhile, the company approved a £122.6 million share buyback through August 2026, aiming to manage capital efficiently. This nuanced analyst sentiment underscores ongoing challenges and opportunities in wealth management amid evolving market and tech landscapes.
Go toTop